Drug Profile
Cannabidiol - Pure Green Pharmaceuticals
Alternative Names: CBD - Pure Green Pharmaceuticals; PG-DN-20WSLatest Information Update: 04 Apr 2023
Price :
$50
*
At a glance
- Originator Pure Green Pharmaceuticals
- Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antiacnes; Antibacterials; Antiepileptic drugs; Antihyperglycaemics; Antihyperlipidaemics; Antineoplastics; Antiparkinsonians; Antipsoriatics; Antipsychotics; Antirheumatics; Anxiolytics; Behavioural disorder therapies; Cannabinoids; Cardiovascular therapies; Cyclohexenes; Drug withdrawal therapies; Heart failure therapies; Hepatoprotectants; Muscle relaxants; Neuroprotectants; Obesity therapies; Resorcinols; Skin disorder therapies; Small molecules
- Mechanism of Action 5-HT1 serotonin receptor modulators; Cannabinoid receptor CB1 inverse agonists; Cannabinoid receptor CB2 inverse agonists; Transient receptor potential channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Neuropathic pain
- Phase I Pain
Most Recent Events
- 30 Mar 2023 Phase-I clinical trials in Pain in USA (PO) before March 2023 (Pure Green Pharmaceuticals pipeline, March 2023)
- 30 Mar 2023 Pure Green Pharmaceuticals intends to initiate regulatory fillings in Europe, Canada and the rest of the world (before March 2023) (Pure Green Pharmaceuticals Pipeline, March 2023)
- 13 May 2021 Efficacy and adverse events data from a phase I trial in Neuropathic pain released by Pure Green Pharmaceuticals